Clinical trial · Observational
Osteosarcoma and Ewing Sarcoma Treatment Response Assessment With Functional MRI Imaging in Children and Young Adults
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study was to investigate whether functional MRI imaging (diffusion weighted imaging) is useful for monitoring the therapeutic response of bone sarcomas in children and young adults. All patients will be scanned before, during and after chemotherapy. The findings on MRI will be correlated with histological finding after surgery. Second purpose : to define apparent diffusion coefficient value of the bone sarcoma. Third purpose : to try define prognostic factors, to investigate if there is a correlation between early treatment response and outcome.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ewing Sarcoma | Ewing Sarcoma | ONTOLOGY_EXACT | 0.98 |
| Osteosarcoma | Osteosarcoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Osteosarcoma
- description
- All patients with Osteosarcoma), proven by surgical biopsy and histopathology. All included patients will be treated by chemotherapy (EURAMOS protocol) An MRI will be performed before, during and post-treatment
- interventionNames
- Other: MRI
- label
- Ewing Sarcoma
- description
- All patients with proven diagnosis of Ewing sarcoma, proven by surgical biopsy and histopathology. All included patients will be treated by chemotherapy (EURO-EWING protocol) An MRI will be performed in all included patients before, during and after the chemotherapy
- interventionNames
- Other: MRI
Primary outcomes (1)
- measure
- tumor necrosis - therapy response
- timeFrame
- 6 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 6 Years
- Maximum age
- 30 Years
Show eligibility criteria text
Inclusion Criteria: * Ewing or Osteosarcoma, proven by biopsy and histopathology * all patients are treated by chemotherapy defined by EURAMOS and EURO-EWING protocol Exclusion Criteria: * Patients under the age of 6 years old * patients with contra-indication for MR exam (pace-maker...) * Patients with renal insufficiency * Claustrophobia
References
Publications (0)
Data not yet available